On October 8, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) reported that its collaboration with Bristol Myers Squibb (NYSE: BMY) has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec (Press release, Evotec, OCT 8, 2021, View Source;announcements/press-releases/p/evotec-expands-neuroscience-collaboration-with-bristol-myers-squibb-to-include-novel-cell-type-6100 [SID1234591011]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is tremendous unmet medical need for therapeutic options that slow down or reverse disease progression. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s iPSC platform using patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.

Since 2016, the companies have expanded the collaboration several times. The latest expansion will enable the companies to investigate the root causes of many neurodegenerative diseases in a cell type specific fashion using cells directly derived from patients. In addition, molecular disease signatures will be used to define detailed molecular disease phenotypes using Evotec’s leading panomics platform, EVOpanOmics & EVOpanHunter.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are delighted that our important collaboration with Bristol Myers Squibb will now investigate and target mechanisms driving neurodegeneration more comprehensively through the addition of a new cell type. Through our human iPSC-based approach we believe we have the potential to improve clinical outcomes of neurodegeneration programmes. iPSC technology enables us to directly work on human neurons to explore new drug candidates in the pre-clinical setting."

On October 7, 2021 AbClon (174900, CEO Jong-seo Lee) a bio venture company and Ebixgen(CEO Yoo Ji-chang) reported a business agreement(MOU) on joint research and development of antibody new drugs with increased tissue permeability (Press release, AbClon, OCT 7, 2021, View Source;wr_id=148&page=2 [SID1234638670]). It was announced on 07 that the agreement was concluded. The two companies signed an MTA (material transfer agreement >, last 8month)With this MOU, we will continue to promote joint research and development of new antibody drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An official of AbClon said, "According to this agreement, Antibodies discovered using AbClone’s antibody and epitope discovery technologyNESTplatform are transferred to Ebixgen’s drug delivery platform. We plan to conduct joint research to develop new antibody drugs that increase the cell delivery ability of drugs by applying them to ACP"< /span>. "by developing innovative new antibody drugs with improved pharmacological efficacy and safety. He emphasized, "We expect to be able to expand to areas that existing antibody treatments cannot solve" said

AbClon is a specific epitope of an antigen(binding site) NEST (Novel Epitope), a technology to discover antibodies that bind to Screening Technology) has a platform. Via the NESTplatform Discovered AC101(stomach cancer, breast cancer antibody treatment< a i=13>) is affiliated with Shanghai Henlius Biotech(Shangahi Henlius Biotech) in China. Technology transfer(L/O)year and clinical trial2ahead. . In addition, its own antibody that binds to a new epitope of the disease protein CD19 Developed, applied it CAR-T cell therapy IND< /span>. month6 It was submitted last Phase1 Domestic clinical trial of AT101

Ebixgen possesses ACP (Advanced Cell Penetrating Peptide technology)technology, which is a new drug development platform technology and next-generation cell and tissue penetration delivery technology. Doing. This is a technology that improves the penetration and delivery ability of drugs that act on cells and tissues. In particular, the blood-brain barrier of drugs(BBB) ​​increasing the permeability of drugs, which is the biggest challenge in the development of existing treatments for brain diseases a>BBB It is characterized by being able to solve the transmission problem. Also, several poorly soluble It can dramatically increase the low solubility, which is a limitation of the drug, thereby increasing the usefulness of poorly soluble drugs with limited application. It is a technology that can expand and improve indications. The company currently treats AIDS, age-related macular degeneration, dry eye disease, < /span>. We have a variety of pipelines, including treatments for atopic dermatitis.

Meanwhile, cell and tissue penetration of drugs, etc. Involved’Drug Delivery System(DDS, Drug Delivery System)’ Is As the final stage of new drug development, controlling the speed of drug application and minimizing side effects are the key to technological prowess . Depending on the size or charge of the new drug candidate, the drug There are many cases where it cannot pass through the inside of the cell, and various DDS Technology is being researched.

On October 7, 2021 Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, reported that it has commenced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock (Press release, Cidara Therapeutics, OCT 7, 2021, View Source [SID1234636984]). With respect to the common stock offering, Cidara also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price. The closing of each proposed offering is not contingent upon the closing of the other. The offerings are subject to market conditions, and there can be no assurance as to whether or when either or both of the offerings will be completed, or as to the actual size or terms of the offerings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald & Co. is acting as the sole book-running manager for each offering.

The securities described above are being offered by Cidara pursuant to a shelf registration statement, which has been declared effective by the Securities and Exchange Commission (SEC). Preliminary prospectus supplements and the accompanying prospectus relating to the offerings will be filed with the SEC and will be available for free on the SEC’s website at View Source Copies of the preliminary prospectus supplements and accompanying prospectus relating to these offerings, when available, may be obtained from: Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 4th Floor, New York, New York 10022, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On October 7, 2021 ALX Oncology Holdings Inc. ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. ("ScalmiBio") reported that ALX Oncology has acquired ScalmiBio (Press release, ALX Oncology, OCT 7, 2021, View Source [SID1234591870]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALX Oncology further expands its pipeline with plans to develop new anti-cancer drug candidates based on ScalmiBio’s platform; these new molecules will be designed to address unmet cancer patient needs as stand-alone therapeutics and in combination with ALX Oncology’s lead product candidate, evorpacept, a next-generation CD47 blocker designed to leverage the immune activation of broadly used anti-cancer agents through combination strategies.

"ALX Oncology was founded to address limitations of CD47 blockade through protein engineering," said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. "ScalmiBio’s universal SHIELD technology allows us to expand our pipeline and bring more treatment options to patients. We are building on our foundational strength of utilizing protein engineering to more broadly address limitations of other clinically and commercially validated anti-cancer targets through the design of conditionally activated antibodies and novel antibody-drug conjugates or ADCs."

ScalmiBio’s SHIELD technology is designed to minimize interaction of an antibody therapeutic with normal tissue and maximize its target binding capability within tumor microenvironment. Many cancer targets are relatively abundant in cancer cells but also expressed in normal cells leading to on-target, off-tumor toxicities that limit patient access to potentially life changing treatments. ScalmiBio’s conditional activation technology aims to increase therapeutic index by minimizing dose limiting toxicities of existing checkpoint inhibitors and other targeted anti-cancer biologics as well as enable the design of ADCs with higher drug-to-antibody ratios for improved anti-cancer activity. ALX Oncology has also acquired ScalmiBio’s proprietary cytotoxic payloads for the development of ADCs.

Under the terms of the share purchase agreement, ALX Oncology made an initial payment to the stockholders of ScalmiBio at closing on October 4, 2021 of approximately $4.5 million in cash, net of certain expenses and adjustments, and will make an additional payment of $2.0 million in cash at the one-year anniversary of the transaction subject to certain conditions. In addition, ALX Oncology has agreed to pay certain milestones based on the clinical development of the acquired ScalmiBio technology and has also agreed to pay a low single digit royalty on net sales of any products developed from the ScalmiBio acquired technology for a defined term.

On October 7, 2021 Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, reported that, further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.

Sareum’s CSO, Dr John Reader, commented:

"We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones."